NCT03003039View on ClinicalTrials.gov

A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

May 20, 2019

Study Completion Date

May 20, 2019

Conditions
B-Cell Lymphoma
Interventions
BIOLOGICAL

GB241

Single intravenous infusion (IV) 375 mg/m2

BIOLOGICAL

Rituximab

Single intravenous infusion (IV) 375 mg/m2

Trial Locations (1)

100076

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Nanjing Yoko Biomedical Co., Ltd.

INDUSTRY

NCT03003039 - A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter